VIOLIN Logo
VO Banner
Search: for Help
Vaxjo Home
Introduction
Statistics
News and Updates
Vaxjo Query
Selected Adjuvants
adamantylamide dipeptide vaccine adjuvant
aluminum hydroxide vaccine adjuvant
alhydrogel vaccine adjuvant
Data Submission
Data Exchange
Data Download
Documentation
FAQs
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

Allogeneic GM-CSF-Based Myeloma Cell Vaccine
Vaccine Information
  • Vaccine Name: Allogeneic GM-CSF-Based Myeloma Cell Vaccine
  • Vaccine Ontology ID: VO_0007223
  • Type: DNA vaccine
  • Status: Clinical trial
  • Host Species for Licensed Use: Human
  • Host Species as Laboratory Animal Model: Human
  • Antigen: GM-CSF
  • GM-CSF (human) gene engineering:
    • Type: cell transfection
    • Detailed Gene Information: Click Here.
  • MAGEA3 gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • WT1 gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • MAGEC1 gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant: GM-CSF vaccine adjuvant
  • Preparation: An MM GVAX is being evaluated in which cells from 2 myeloma cell lines are admixed with K562 cells modified to express GM-CSF (Garfall and Stadtmauer, 2016).
  • Description: An allogeneic tumor cell vaccine containing myeloma cancer cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene with potential antineoplastic activity. Upon vaccination, allogeneic GM-CSF-based myeloma cellular vaccine secretes GM-CSF, which may potentiate a tumor-specific cytotoxic T-lymphocyte (CTL) response against myeloma cancer cell-associated antigens. (NCIT_C90540).
References
Garfall and Stadtmauer, 2016: Garfall AL, Stadtmauer EA. Cellular and vaccine immunotherapy for multiple myeloma. Hematology. American Society of Hematology. Education Program. 2016; 2016(1); 521-527. [PubMed: 27913524].
NCIT_C90540: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C90540]
Allogeneic GM-CSF-Secreting Breast Cancer Vaccine
Vaccine Information
  • Vaccine Name: Allogeneic GM-CSF-Secreting Breast Cancer Vaccine
  • Vaccine Ontology ID: VO_0007224
  • Type: DNA vaccine
  • Status: Clinical trial
  • Host Species for Licensed Use: Human
  • Host Species as Laboratory Animal Model: Human
  • GM-CSF (human) gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • ERBB2 gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant: GM-CSF vaccine adjuvant
  • Preparation: The parent cell lines T47D (HER2low) and SKBR3 (HER2high) were genetically modified by plasmid DNA transfection to secrete GM-CSF. Clinical lots were prepared from two subcloned cell lines secreting bioactive levels of GM-CSF, 2T47D-V and 3SKBR3-7. On D0, serum-free, cryopreserved, irradiated vaccine cells were thawed and mixed to create a HER2+ vaccine that secreted GM-CSF levels of about 300 ng/106 cells /24 hours (Chen et al., 2014).
  • Description: An allogenic vaccine consisting of irradiated breast cancer cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene. Upon vaccination, the genetically modified cells secrete GM-CSF, thereby potentiating a tumor-specific T cell response against breast cancer cell-asociated antigens.A vaccine that is being studied as a way to help the body's immune system kill breast cancer cells. To make the vaccine, the GM-CSF gene is put into breast cancer cells in the laboratory. The cells are then treated with radiation to stop them from growing and injected into the same or a different patient. The GM-CSF protein made by the changed breast cancer cells may help the immune system kill breast cancer cells in the body. (NCIT_C48371).
References
Chen et al., 2014: Chen G, Gupta R, Petrik S, Laiko M, Leatherman JM, Asquith JM, Daphtary MM, Garrett-Mayer E, Davidson NE, Hirt K, Berg M, Uram JN, Dauses T, Fetting J, Duus EM, Atay-Rosenthal S, Ye X, Wolff AC, Stearns V, Jaffee EM, Emens LA. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. Cancer immunology research. 2014; 2(10); 949-961. [PubMed: 25116755].
NCIT_C48371: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48371]
Allogeneic GM-CSF-secreting Tumor Vaccine PANC 10.05 pcDNA-1/GM-Neo
Vaccine Information
  • Vaccine Name: Allogeneic GM-CSF-secreting Tumor Vaccine PANC 10.05 pcDNA-1/GM-Neo
  • Vaccine Ontology ID: VO_0007225
  • Type: DNA vaccine
  • Status: Clinical trial
  • Host Species for Licensed Use: Human
  • Host Species as Laboratory Animal Model: Human
  • GM-CSF (human) gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant: GM-CSF vaccine adjuvant
  • Description: An allogeneic cancer vaccine composed of lethally irradiated, whole pancreatic cancer cells transfected with a plasmid carrying the gene for cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Allogeneic GM-CSF-secreting tumor vaccine PANC 10.05 pcDNA-1/GM-Neo secretes GM-CSF thereby activating dendritic cells, promoting antigen presentation to B- and T-cells, and promoting a cytotoxic T-lymphocyte (CTL) response. This may eventually kill tumor cells. The pancreatic tumor cells are derived from the PANC 10.05 tumor cell line. (NCIT_C101892).

    Allogenic pancreatic tumor cell vaccine transfected with the granulocyte macrophage colony-stimulating factor (GM-CSF) gene alone or given in combination with either a single intravenous dose or daily metronomic oral doses of cyclophosphamide has been used for the treatment of patients with surgically resected adenocarcinoma of the head, neck, tail or the uncinate process of the pancreas. NCT01088789
References
NCIT_C101892: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C101892]
Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo
Vaccine Information
  • Vaccine Name: Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo
  • Vaccine Ontology ID: VO_0007226
  • Type: DNA vaccine
  • Status: Clinical trial
  • Host Species for Licensed Use: Human
  • Host Species as Laboratory Animal Model: Human
  • GM-CSF (human) gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant: GM-CSF vaccine adjuvant
  • Description: An allogeneic cancer vaccine composed of lethally irradiated, whole pancreatic cancer cells transfected with a plasmid carrying the gene for cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Allogeneic GM-CSF-secreting tumor vaccine PANC 6.03 pcDNA-1/GM-Neo secretes GM-CSF thereby activating dendritic cells, promoting antigen presentation to B- and T-cells, and promoting a cytotoxic T-lymphocyte (CTL) response. This may eventually kill tumor cells. The pancreatic tumor cells are derived from the PANC 6.03 tumor cell line. (NCIT_C101891).

    Allogenic pancreatic tumor cell vaccine transfected with the granulocyte macrophage colony-stimulating factor (GM-CSF) gene alone or given in combination with either a single intravenous dose or daily metronomic oral doses of cyclophosphamide has been used for the treatment of patients with surgically resected adenocarcinoma of the head, neck, tail or the uncinate process of the pancreas. NCT01088789
References
NCIT_C101891: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C101891]
gp100 and GM-CSF DNA/Gold Vaccine
Vaccine Information
  • Vaccine Name: gp100 and GM-CSF DNA/Gold Vaccine
  • Vaccine Ontology ID: VO_0007483
  • Type: DNA vaccine
  • Status: Clinical trial
  • Host Species for Licensed Use: Human
  • Host Species as Laboratory Animal Model: Human
  • Antigen: gp100
  • gp100 (PMEL) gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant: GM-CSF vaccine adjuvant
  • Description: A vaccine consisting of microscopic gold particles coated with plasmid DNA encoding the glycoprotein 100 (gp100) melanoma antigen and granulocyte-macrophage colony-stimulating factor (GM-CSF). Vaccination with gp100 and GM-CSF DNA/gold vaccine may stimulate the host immune system to direct cytotoxic T lymphocytes (CTL) against gp100 positive cells, resulting in decreased tumor growth. GM-CSF is thought to increase the induction and activation of antigen-presenting cells (APC), allowing for a reduction in the dose of gp100 administered. (NCI04) (NCIT_C2760).
References
NCIT_C2760: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2760]
Mouse gp100 Plasmid DNA Vaccine
Vaccine Information
  • Vaccine Name: Mouse gp100 Plasmid DNA Vaccine
  • Vaccine Ontology ID: VO_0007528
  • Type: DNA vaccine
  • Status: Clinical trial
  • Host Species for Licensed Use: Human
  • Host Species as Laboratory Animal Model: Human
  • Antigen: gp100
  • Pmel17 gene engineering:
  • Adjuvant: GM-CSF vaccine adjuvant
  • Description: A vaccine consisting of a plasmid DNA encoding the murine melanoma-associated antigen gp100. Upon administration, expressed gp100 antigen may stimulate a cytotoxic T cell HLA-A2.1-restricted immune response against tumor cells that express the gp100 antigen, resulting in tumor cell lysis. (NCI05) (NCIT_C48410).
References
NCIT_C48410: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48410]
Rakhmilevich et al., 2001: Rakhmilevich AL, Imboden M, Hao Z, Macklin MD, Roberts T, Wright KM, Albertini MR, Yang NS, Sondel PM. Effective particle-mediated vaccination against mouse melanoma by coadministration of plasmid DNA encoding Gp100 and granulocyte-macrophage colony-stimulating factor. Clinical cancer research : an official journal of the American Association for Cancer Research. 2001; 7(4); 952-961. [PubMed: 11309346].
VCL-CB01 Vaccine
Vaccine Information
  • Vaccine Name: VCL-CB01 Vaccine
  • Vaccine Ontology ID: VO_0007054
  • Type: DNA vaccine
  • Status: Clinical trial
  • Host Species for Licensed Use: Human
  • Host Species as Laboratory Animal Model: Human
  • UL83 gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant: CRL1005 vaccine adjuvant
  • Preparation: The vaccine contained plasmids encoding cytomegalovirus glycoprotein B and phosphoprotein 65, each at 2·5 mg/mL (ie, 5 mg overall per mL), formulated with poloxamer CRL1005 and benzalkonium chloride in phosphate-buffered saline (Kharfan-Dabaja et al., 2012).
  • Description: This is for Leukemia Cancer and Lymphoma Cancer (NCT00285259). A vaccine consisting of two plasmids encoding the human cytomegalovirus (CMV) tegument phosphoprotein 65 (pp65), a major internal matrix protein, and glycoprotein B (gB), an important CMV component responsible for attachment and entry into cells, with immunostimulatory properties. Vaccination with VCL-CB01 may stimulate the host immune system to mount cellular and humoral immune responses against CMV positive cells, resulting in cell lysis (Kharfan-Dabaja et al., 2012; NCIT_C61327).
References
Kharfan-Dabaja et al., 2012: Kharfan-Dabaja MA, Boeckh M, Wilck MB, Langston AA, Chu AH, Wloch MK, Guterwill DF, Smith LR, Rolland AP, Kenney RT. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. Infectious diseases. 2012; 12(4); 290-299. [PubMed: 22237175].
NCIT_C61327: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61327]
NCT00285259: [https://clinicaltrials.gov/show/NCT00285259]